Literature DB >> 25840600

Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.

Meletios A Dimopoulos1, Maria T Petrucci2, Robin Foà2, John Catalano3, Martin Kropff4, Evangelos Terpos5, Jingshan Zhang6, Lara Grote6, Christian Jacques6, Antonio Palumbo7.   

Abstract

Entities:  

Keywords:  MM-015; PFS2; lenalidomide; maintenance; newly diagnosed multiple myeloma (NDMM)

Mesh：

Year:  2015        PMID： 25840600      PMCID： PMC5004436          DOI： 10.3324/haematol.2014.120790

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Progression-free survival: meaningful or simply measurable?

Authors:  Christopher M Booth; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

2.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Authors:  Antonio Palumbo; Sara Bringhen; Alessandra Larocca; Davide Rossi; Francesco Di Raimondo; Valeria Magarotto; Francesca Patriarca; Anna Levi; Giulia Benevolo; Iolanda Donatella Vincelli; Mariella Grasso; Luca Franceschini; Daniela Gottardi; Renato Zambello; Vittorio Montefusco; Antonietta Pia Falcone; Paola Omedé; Roberto Marasca; Fortunato Morabito; Roberto Mina; Tommasina Guglielmelli; Chiara Nozzoli; Roberto Passera; Gianluca Gaidano; Massimo Offidani; Roberto Ria; Maria Teresa Petrucci; Pellegrino Musto; Mario Boccadoro; Michele Cavo
Journal:  J Clin Oncol       Date:  2014-01-21       Impact factor: 44.544

3.  Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authors:  Lotfi Benboubker; Meletios A Dimopoulos; Angela Dispenzieri; John Catalano; Andrew R Belch; Michele Cavo; Antonello Pinto; Katja Weisel; Heinz Ludwig; Nizar Bahlis; Anne Banos; Mourad Tiab; Michel Delforge; Jamie Cavenagh; Catarina Geraldes; Je-Jung Lee; Christine Chen; Albert Oriol; Javier de la Rubia; Lugui Qiu; Darrell J White; Daniel Binder; Kenneth Anderson; Jean-Paul Fermand; Philippe Moreau; Michel Attal; Robert Knight; Guang Chen; Jason Van Oostendorp; Christian Jacques; Annette Ervin-Haynes; Hervé Avet-Loiseau; Cyrille Hulin; Thierry Facon
Journal:  N Engl J Med       Date:  2014-09-04       Impact factor: 91.245

4.  Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

Authors:  Jesus San Miguel; Katja Weisel; Philippe Moreau; Martha Lacy; Kevin Song; Michel Delforge; Lionel Karlin; Hartmut Goldschmidt; Anne Banos; Albert Oriol; Adrian Alegre; Christine Chen; Michele Cavo; Laurent Garderet; Valentina Ivanova; Joaquin Martinez-Lopez; Andrew Belch; Antonio Palumbo; Stephen Schey; Pieter Sonneveld; Xin Yu; Lars Sternas; Christian Jacques; Mohamed Zaki; Meletios Dimopoulos
Journal:  Lancet Oncol       Date:  2013-09-03       Impact factor: 41.316

5.  The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.

Authors:  Gareth J Morgan; Walter M Gregory; Faith E Davies; Sue E Bell; Alexander J Szubert; Julia M Brown; Nuria N Coy; Gordon Cook; Nigel H Russell; Claudius Rudin; Huw Roddie; Mark T Drayson; Roger G Owen; Fiona M Ross; Graham H Jackson; J Anthony Child
Journal:  Blood       Date:  2011-10-20       Impact factor: 22.113

Review 6.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

7.  A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.

Authors:  David S Siegel; Thomas Martin; Michael Wang; Ravi Vij; Andrzej J Jakubowiak; Sagar Lonial; Suzanne Trudel; Vishal Kukreti; Nizar Bahlis; Melissa Alsina; Asher Chanan-Khan; Francis Buadi; Frederic J Reu; George Somlo; Jeffrey Zonder; Kevin Song; A Keith Stewart; Edward Stadtmauer; Lori Kunkel; Sandra Wear; Alvin F Wong; Robert Z Orlowski; Sundar Jagannath
Journal:  Blood       Date:  2012-07-25       Impact factor: 22.113

8.  Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Authors:  Antonio Palumbo; Roman Hajek; Michel Delforge; Martin Kropff; Maria Teresa Petrucci; John Catalano; Heinz Gisslinger; Wiesław Wiktor-Jędrzejczak; Mamia Zodelava; Katja Weisel; Nicola Cascavilla; Genadi Iosava; Michele Cavo; Janusz Kloczko; Joan Bladé; Meral Beksac; Ivan Spicka; Torben Plesner; Joergen Radke; Christian Langer; Dina Ben Yehuda; Alessandro Corso; Lindsay Herbein; Zhinuan Yu; Jay Mei; Christian Jacques; Meletios A Dimopoulos
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

9.  Lenalidomide after stem-cell transplantation for multiple myeloma.

Authors:  Philip L McCarthy; Kouros Owzar; Craig C Hofmeister; David D Hurd; Hani Hassoun; Paul G Richardson; Sergio Giralt; Edward A Stadtmauer; Daniel J Weisdorf; Ravi Vij; Jan S Moreb; Natalie Scott Callander; Koen Van Besien; Teresa Gentile; Luis Isola; Richard T Maziarz; Don A Gabriel; Asad Bashey; Heather Landau; Thomas Martin; Muzaffar H Qazilbash; Denise Levitan; Brian McClune; Robert Schlossman; Vera Hars; John Postiglione; Chen Jiang; Elizabeth Bennett; Susan Barry; Linda Bressler; Michael Kelly; Michele Seiler; Cara Rosenbaum; Parameswaran Hari; Marcelo C Pasquini; Mary M Horowitz; Thomas C Shea; Steven M Devine; Kenneth C Anderson; Charles Linker
Journal:  N Engl J Med       Date:  2012-05-10       Impact factor: 91.245

10.  Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: a meta-analysis of randomized controlled trials.

Authors:  Xueshi Ye; Jinwen Huang; Qin Pan; Wanli Li
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240
View more
  5 in total

Review 1.  Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State.

Authors:  Petros Grivas; Bradley J Monk; Daniel Petrylak; Martin Reck; Grace Foley; Silke Guenther; Dan Hennessy; Constantin Makris; Markus Moehler
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

2.  Effect of Lenalidomide Maintenance in Chronic Lymphocytic Leukemia: A Meta-Analysis and Trial-Sequential Analysis.

Authors:  Tsung-Ying Yu; Hong-Jie Jhou; Po-Huang Chen; Cho-Hao Lee
Journal:  Curr Oncol       Date:  2022-06-14       Impact factor: 3.109

Review 3.  Anakoinosis: Correcting Aberrant Homeostasis of Cancer Tissue-Going Beyond Apoptosis Induction.

Authors:  Daniel Heudobler; Florian Lüke; Martin Vogelhuber; Sebastian Klobuch; Tobias Pukrop; Wolfgang Herr; Christopher Gerner; Pan Pantziarka; Lina Ghibelli; Albrecht Reichle
Journal:  Front Oncol       Date:  2019-12-20       Impact factor: 6.244

Review 4.  Recent advances in the management of older adults with newly diagnosed multiple myeloma in Japan.

Authors:  Tomotaka Suzuki; Dai Maruyama; Shinsuke Iida; Hirokazu Nagai
Journal:  Jpn J Clin Oncol       Date:  2022-09-18       Impact factor: 2.925

5.  Conference report on the 28th annual meeting of the European Musculo-Skeletal Oncology Society, 29 April-1 May 2015, Athens.

Authors:  Andreas Leithner; Dimosthenis Andreou; Robert Grimer; Stefano Ferrari; Georg Gosheger; Panayiotis J Papagelopoulos; Stefan S Bielack
Journal:  Ecancermedicalscience       Date:  2015-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.